Caricamento...
Skeletal responses to romosozumab after 12 months of denosumab
Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects of romosozumab after 12 months of denosumab in postmenopausal...
Salvato in:
| Pubblicato in: | JBMR Plus |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Inc.
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8260819/ https://ncbi.nlm.nih.gov/pubmed/34258507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10512 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|